Peer-reviewed veterinary case report
Telmisartan lowers protein in urine and blood pressure in dogs
By Miyagawa, Yuichi et al.·Published in Research in veterinary science·2020·School of Veterinary Medicine, Japan·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Effects of telmisartan on proteinuria and systolic blood pressure in dogs with chronic kidney disease.
- Species:
- dog
Plain-English summary
A group of 28 dogs with chronic kidney disease (CKD) and protein in their urine were treated with telmisartan, a medication that helps lower blood pressure and reduce proteinuria. After 120 days, many of the dogs showed significant improvements: their urine protein levels and blood pressure decreased, with some dogs reaching normal protein levels. This treatment helped about 37% of the dogs achieve a healthy urine protein level, and nearly 60% of those with high blood pressure saw their levels drop to a safer range. Overall, telmisartan proved effective in managing both proteinuria and hypertension in these dogs.
People also search for: dog chronic kidney disease treatment · telmisartan for dogs · dog protein in urine symptoms
Abstract
Renal proteinuria is associated with promoted renal dysfunction and a shorter survival period in dogs with chronic kidney disease (CKD). Renin angiotensin- aldosterone system inhibitors are primarily used to treat renal proteinuria. In this retrospective, open-label study, we aimed to evaluate the anti-proteinuric and anti-hypertensive effects of telmisartan (angiotensin II receptor blocker) in dogs with proteinuric CKD. A total of 28 dogs with proteinuric CKD were included in the study, all dogs received telmisartan 1 mg/kg q24h, PO. The urine protein-to-creatinine ratio (UPC), urine albumin-to-creatinine ratio (UAC) and systolic blood pressure (SBP) decreased significantly after telmisartan administration (P < 0.05). The median rate of change in UPC, UAC and SBP at Day 120 were - 65.1%, -75.9% and - 9.7%. Ten dogs (36.7%) achieved UPC < 1.0 at Day 120, of which six dogs had UPC < 0.5. A reduction of UPC to ≥50% was achieved in 10 dogs (36%) at Day 45 and 17 dogs (61%) at Day 120. Seventeen dogs (61%) had hypertension at baseline, of which 10 dogs (59%) had SBP < 160 mmHg at Day 120. Two-way repeated measures analysis of variance did not attribute the observed changes in SBP, UPC or UAC to feeding with a renal diet. In conclusion, telmisartan therapy provides anti-proteinuric and anti-hypertensive effects in dogs with proteinuric CKD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32992126/